Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00798889 · ClinicalTrials.gov registry record · NA
Rollover Protocol for Prior SU011248 Protocols
A NA study, sponsored by Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 314
- Enrollment target
NCT00798889: Completed NA study, sponsored by Pfizer.
NCT00798889 is a NA study that has completed, run by Pfizer. The registered enrollment target is 314 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00798889, a NA study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 314 participants
- Enrollment target
Study Summary
The objective of this protocol is to provide SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol
Interventions
- DRUG Sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2004-03 |
| Est. Completion | 2011-12 |
| Phase | NA |
What the finished NCT00798889 record still lists
NCT00798889 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 1 intervention - of which Sunitinib is the first listed.
NCT00798889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00798889 about?
NCT00798889 is a clinical study titled "Rollover Protocol for Prior SU011248 Protocols". The objective of this protocol is to provide SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol
What is the current status of trial NCT00798889?
This trial is currently completed. It is a NA study. The enrollment target is 314 participants. The study started on 2004-03. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00798889?
The interventions under investigation include: Sunitinib (DRUG).
Who is sponsoring clinical trial NCT00798889?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00798889's enrollment target sits among peer trials
314 323rd of 2000 higher than 1,678 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT06883097 · 314 participants · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia